CN107849014B - 一种联苯衍生物及其制备方法和在医药上的用途 - Google Patents
一种联苯衍生物及其制备方法和在医药上的用途 Download PDFInfo
- Publication number
- CN107849014B CN107849014B CN201680042175.6A CN201680042175A CN107849014B CN 107849014 B CN107849014 B CN 107849014B CN 201680042175 A CN201680042175 A CN 201680042175A CN 107849014 B CN107849014 B CN 107849014B
- Authority
- CN
- China
- Prior art keywords
- ethyl
- oxo
- phenylphenyl
- alkyl
- carbamate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title abstract description 14
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical class C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 78
- 239000003814 drug Substances 0.000 claims abstract description 19
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 258
- -1 cyano, methyl Chemical group 0.000 claims description 200
- 229910052794 bromium Inorganic materials 0.000 claims description 67
- 229910052801 chlorine Inorganic materials 0.000 claims description 67
- 229910052731 fluorine Inorganic materials 0.000 claims description 67
- 229910052740 iodine Inorganic materials 0.000 claims description 62
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 50
- 150000003254 radicals Chemical class 0.000 claims description 48
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 44
- 125000001424 substituent group Chemical group 0.000 claims description 43
- 125000000217 alkyl group Chemical group 0.000 claims description 34
- 239000000203 mixture Substances 0.000 claims description 27
- 125000003545 alkoxy group Chemical group 0.000 claims description 26
- 229910052799 carbon Inorganic materials 0.000 claims description 15
- 125000002947 alkylene group Chemical group 0.000 claims description 13
- 125000000304 alkynyl group Chemical group 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims description 8
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 claims description 7
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 7
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 claims description 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 5
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 5
- 229910017912 NH2OH Inorganic materials 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 5
- 239000003149 muscarinic antagonist Substances 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 4
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 claims description 4
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 claims description 4
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 3
- 206010006451 bronchitis Diseases 0.000 claims description 3
- 208000007451 chronic bronchitis Diseases 0.000 claims description 3
- 239000003246 corticosteroid Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000000808 adrenergic beta-agonist Substances 0.000 claims description 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 208000027771 Obstructive airways disease Diseases 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000013078 crystal Substances 0.000 abstract description 14
- 229940002612 prodrug Drugs 0.000 abstract description 14
- 239000000651 prodrug Substances 0.000 abstract description 14
- 239000012453 solvate Substances 0.000 abstract description 14
- 239000002207 metabolite Substances 0.000 abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 4
- 230000005496 eutectics Effects 0.000 abstract description 3
- 230000000414 obstructive effect Effects 0.000 abstract description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 330
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 168
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 110
- 238000006243 chemical reaction Methods 0.000 description 107
- 230000002829 reductive effect Effects 0.000 description 73
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 71
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 63
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 62
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 60
- 239000012074 organic phase Substances 0.000 description 59
- 239000000460 chlorine Substances 0.000 description 56
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 48
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 44
- 238000004440 column chromatography Methods 0.000 description 42
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 40
- 229920006395 saturated elastomer Polymers 0.000 description 40
- 239000007787 solid Substances 0.000 description 38
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 37
- 235000017557 sodium bicarbonate Nutrition 0.000 description 34
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 34
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 28
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 26
- 238000003756 stirring Methods 0.000 description 26
- 239000000706 filtrate Substances 0.000 description 23
- 238000005160 1H NMR spectroscopy Methods 0.000 description 22
- 239000000243 solution Substances 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 125000000623 heterocyclic group Chemical group 0.000 description 20
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 20
- 239000007788 liquid Substances 0.000 description 19
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- 238000000605 extraction Methods 0.000 description 17
- 239000007864 aqueous solution Substances 0.000 description 15
- AJYJXUDBEJIRAA-UHFFFAOYSA-N carbonic acid;2-phenylaniline Chemical compound OC(O)=O.NC1=CC=CC=C1C1=CC=CC=C1.NC1=CC=CC=C1C1=CC=CC=C1 AJYJXUDBEJIRAA-UHFFFAOYSA-N 0.000 description 15
- 239000011541 reaction mixture Substances 0.000 description 15
- 125000004432 carbon atom Chemical group C* 0.000 description 14
- 239000003208 petroleum Substances 0.000 description 14
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 12
- ANZZCQPQOLRQDD-AWEZNQCLSA-N 5-[(1r)-2-amino-1-[tert-butyl(dimethyl)silyl]oxyethyl]-8-hydroxy-1h-quinolin-2-one Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@H](CN)O[Si](C)(C)C(C)(C)C ANZZCQPQOLRQDD-AWEZNQCLSA-N 0.000 description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
- 125000004452 carbocyclyl group Chemical group 0.000 description 12
- 229910052739 hydrogen Inorganic materials 0.000 description 12
- MBABOKRGFJTBAE-UHFFFAOYSA-N methyl methanesulfonate Chemical compound COS(C)(=O)=O MBABOKRGFJTBAE-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 11
- 239000008346 aqueous phase Substances 0.000 description 11
- 238000010898 silica gel chromatography Methods 0.000 description 11
- 229910052717 sulfur Inorganic materials 0.000 description 11
- 125000004008 6 membered carbocyclic group Chemical group 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- IKGLACJFEHSFNN-UHFFFAOYSA-N hydron;triethylazanium;trifluoride Chemical compound F.F.F.CCN(CC)CC IKGLACJFEHSFNN-UHFFFAOYSA-N 0.000 description 10
- 229910052760 oxygen Inorganic materials 0.000 description 10
- 238000010791 quenching Methods 0.000 description 10
- 125000005999 2-bromoethyl group Chemical group 0.000 description 9
- 125000001072 heteroaryl group Chemical group 0.000 description 9
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 125000002462 isocyano group Chemical group *[N+]#[C-] 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 125000000753 cycloalkyl group Chemical group 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 125000005842 heteroatom Chemical group 0.000 description 8
- 239000001257 hydrogen Substances 0.000 description 8
- 239000012046 mixed solvent Substances 0.000 description 8
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 8
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 7
- ZWQLGKGAUAITHV-UHFFFAOYSA-N 2-[6-[[tert-butyl(dimethyl)silyl]oxymethyl]-4,4-dimethyl-1-oxo-3H-isoquinolin-2-yl]acetaldehyde Chemical compound [Si](C)(C)(C(C)(C)C)OCC=1C=C2C(CN(C(C2=CC=1)=O)CC=O)(C)C ZWQLGKGAUAITHV-UHFFFAOYSA-N 0.000 description 7
- MMYJXHHFFSAHMY-UHFFFAOYSA-N 2-[7-[[tert-butyl(dimethyl)silyl]oxymethyl]-1-oxo-3,4-dihydroisoquinolin-2-yl]acetaldehyde Chemical compound [Si](C)(C)(C(C)(C)C)OCC1=CC=C2CCN(C(C2=C1)=O)CC=O MMYJXHHFFSAHMY-UHFFFAOYSA-N 0.000 description 7
- FQPKKECSRKYXIZ-UHFFFAOYSA-N 6-bromo-3,4-dihydro-2h-isoquinolin-1-one Chemical compound O=C1NCCC2=CC(Br)=CC=C21 FQPKKECSRKYXIZ-UHFFFAOYSA-N 0.000 description 7
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 125000004429 atom Chemical group 0.000 description 7
- 239000007810 chemical reaction solvent Substances 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- GGWLSAWYOBOGKT-UHFFFAOYSA-N 2-[6-[[tert-butyl(dimethyl)silyl]oxymethyl]-1-oxo-3,4-dihydroisoquinolin-2-yl]acetaldehyde Chemical compound [Si](C)(C)(C(C)(C)C)OCC=1C=C2CCN(C(C2=CC=1)=O)CC=O GGWLSAWYOBOGKT-UHFFFAOYSA-N 0.000 description 6
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 241000700198 Cavia Species 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 239000000048 adrenergic agonist Substances 0.000 description 6
- 125000003342 alkenyl group Chemical group 0.000 description 6
- 125000006269 biphenyl-2-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C(*)C([H])=C([H])C([H])=C1[H] 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 6
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 6
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 5
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 5
- 108060003345 Adrenergic Receptor Proteins 0.000 description 5
- 102000017910 Adrenergic receptor Human genes 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 5
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 229940125904 compound 1 Drugs 0.000 description 5
- 229940125797 compound 12 Drugs 0.000 description 5
- 229940125782 compound 2 Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 239000012279 sodium borohydride Substances 0.000 description 5
- 229910000033 sodium borohydride Inorganic materials 0.000 description 5
- BXEMYOYXZCVKRH-LBPRGKRZSA-N 8-[(1r)-2-amino-1-[tert-butyl(dimethyl)silyl]oxyethyl]-5-hydroxy-4h-1,4-benzoxazin-3-one Chemical compound N1C(=O)COC2=C1C(O)=CC=C2[C@H](CN)O[Si](C)(C)C(C)(C)C BXEMYOYXZCVKRH-LBPRGKRZSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 206010006482 Bronchospasm Diseases 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 230000008484 agonism Effects 0.000 description 4
- 230000007885 bronchoconstriction Effects 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- 229940126214 compound 3 Drugs 0.000 description 4
- 230000009977 dual effect Effects 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 125000002541 furyl group Chemical group 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000007800 oxidant agent Substances 0.000 description 4
- 230000001590 oxidative effect Effects 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 4
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 3
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 3
- 102000007202 Muscarinic M3 Receptor Human genes 0.000 description 3
- 108010008405 Muscarinic M3 Receptor Proteins 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 230000001270 agonistic effect Effects 0.000 description 3
- 125000004450 alkenylene group Chemical group 0.000 description 3
- 125000004419 alkynylene group Chemical group 0.000 description 3
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 description 3
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 3
- 125000005997 bromomethyl group Chemical group 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 229940125773 compound 10 Drugs 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 229910052805 deuterium Inorganic materials 0.000 description 3
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 3
- DGODWNOPHMXOTR-UHFFFAOYSA-N dipotassium;dioxido(dioxo)osmium;dihydrate Chemical compound O.O.[K+].[K+].[O-][Os]([O-])(=O)=O DGODWNOPHMXOTR-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 3
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 3
- VYUAAIKZXAXYLO-UHFFFAOYSA-N methyl 1-oxo-2-[2-[4-[(2-phenylphenyl)carbamoyloxy]piperidin-1-yl]ethyl]-3H-isoindole-5-carboxylate Chemical compound O=C1N(CC2=CC(=CC=C12)C(=O)OC)CCN1CCC(CC1)OC(NC1=C(C=CC=C1)C1=CC=CC=C1)=O VYUAAIKZXAXYLO-UHFFFAOYSA-N 0.000 description 3
- 125000002971 oxazolyl group Chemical group 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 125000003226 pyrazolyl group Chemical group 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 3
- 235000019345 sodium thiosulphate Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 125000006633 tert-butoxycarbonylamino group Chemical group 0.000 description 3
- 125000000335 thiazolyl group Chemical group 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 description 2
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 description 2
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 description 2
- 125000006040 2-hexenyl group Chemical group 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- XFDUHJPVQKIXHO-UHFFFAOYSA-N 3-aminobenzoic acid Chemical compound NC1=CC=CC(C(O)=O)=C1 XFDUHJPVQKIXHO-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- GZDRZVDTUXFZEY-UHFFFAOYSA-N 6-bromo-4,4-dimethyl-2,3-dihydroisoquinolin-1-one Chemical compound C1=C(Br)C=C2C(C)(C)CNC(=O)C2=C1 GZDRZVDTUXFZEY-UHFFFAOYSA-N 0.000 description 2
- ZPYHQFRRUXPORK-INIZCTEOSA-N 7-[(1R)-2-amino-1-[tert-butyl(dimethyl)silyl]oxyethyl]-4-[tert-butyl(dimethyl)silyl]oxy-3H-1,3-benzothiazol-2-one Chemical compound NC[C@H](O[Si](C)(C)C(C)(C)C)C1=CC=C(C=2NC(SC=21)=O)O[Si](C)(C)C(C)(C)C ZPYHQFRRUXPORK-INIZCTEOSA-N 0.000 description 2
- DRDDOAWCDDBYHZ-UHFFFAOYSA-N 7-bromo-3,4-dihydro-2h-isoquinolin-1-one Chemical compound C1CNC(=O)C2=CC(Br)=CC=C21 DRDDOAWCDDBYHZ-UHFFFAOYSA-N 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 239000012448 Lithium borohydride Substances 0.000 description 2
- 241000989747 Maba Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010084455 Zeocin Proteins 0.000 description 2
- WXVOXSMBQVYSMU-DHUJRADRSA-N [1-[2-[6-[2-[[(2R)-2-hydroxy-2-(4-hydroxy-2-oxo-3H-1,3-benzothiazol-7-yl)ethyl]amino]ethyl]-1-oxo-3,4-dihydroisoquinolin-2-yl]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate Chemical compound O[C@@H](CNCCC=1C=C2CCN(C(C2=CC=1)=O)CCN1CCC(CC1)OC(NC1=C(C=CC=C1)C1=CC=CC=C1)=O)C1=CC=C(C=2NC(SC=21)=O)O WXVOXSMBQVYSMU-DHUJRADRSA-N 0.000 description 2
- LAYBWZXTOJLFEP-BHVANESWSA-N [1-[2-[6-[2-[[(2R)-2-hydroxy-2-(5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]-1-oxo-3,4-dihydroisoquinolin-2-yl]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate Chemical compound O[C@@H](CNCCC=1C=C2CCN(C(C2=CC=1)=O)CCN1CCC(CC1)OC(NC1=C(C=CC=C1)C1=CC=CC=C1)=O)C1=CC=C(C=2NC(COC=21)=O)O LAYBWZXTOJLFEP-BHVANESWSA-N 0.000 description 2
- HOOUKGJQMOVCPT-LHEWISCISA-N [1-[2-[6-[2-[[(2R)-2-hydroxy-2-(8-hydroxy-2-oxo-1H-quinolin-5-yl)ethyl]amino]ethyl]-1-oxo-3,4-dihydroisoquinolin-2-yl]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate Chemical compound O[C@@H](CNCCC=1C=C2CCN(C(C2=CC=1)=O)CCN1CCC(CC1)OC(NC1=C(C=CC=C1)C1=CC=CC=C1)=O)C1=C2C=CC(NC2=C(C=C1)O)=O HOOUKGJQMOVCPT-LHEWISCISA-N 0.000 description 2
- FCJGZZKPJZRJFT-QNGWXLTQSA-N [1-[2-[6-[2-[[(2R)-2-hydroxy-2-(8-hydroxy-2-oxo-1H-quinolin-5-yl)ethyl]amino]ethyl]-3-oxo-1H-isoindol-2-yl]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate Chemical compound O[C@@H](CNCCC=1C=C2CN(C(C2=CC=1)=O)CCN1CCC(CC1)OC(NC1=C(C=CC=C1)C1=CC=CC=C1)=O)C1=C2C=CC(NC2=C(C=C1)O)=O FCJGZZKPJZRJFT-QNGWXLTQSA-N 0.000 description 2
- MXAVYGWNLZMWHV-UMSFTDKQSA-N [1-[2-[6-[[[(2R)-2-hydroxy-2-(4-hydroxy-2-oxo-3H-1,3-benzothiazol-7-yl)ethyl]amino]methyl]-1-oxo-3,4-dihydroisoquinolin-2-yl]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate Chemical compound O[C@@H](CNCC=1C=C2CCN(C(C2=CC=1)=O)CCN1CCC(CC1)OC(NC1=C(C=CC=C1)C1=CC=CC=C1)=O)C1=CC=C(C=2NC(SC=21)=O)O MXAVYGWNLZMWHV-UMSFTDKQSA-N 0.000 description 2
- OZMDPTLHXHLIIJ-QNGWXLTQSA-N [1-[2-[6-[[[(2R)-2-hydroxy-2-(8-hydroxy-2-oxo-1H-quinolin-5-yl)ethyl]amino]methyl]-1-oxo-3,4-dihydroisoquinolin-2-yl]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate Chemical compound O[C@@H](CNCC=1C=C2CCN(C(C2=CC=1)=O)CCN1CCC(CC1)OC(NC1=C(C=CC=C1)C1=CC=CC=C1)=O)C1=C2C=CC(NC2=C(C=C1)O)=O OZMDPTLHXHLIIJ-QNGWXLTQSA-N 0.000 description 2
- AUFQZFWXAANTNY-BHVANESWSA-N [1-[2-[6-[[[(2R)-2-hydroxy-2-(8-hydroxy-2-oxo-1H-quinolin-5-yl)ethyl]amino]methyl]-3-oxo-1H-isoindol-2-yl]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate Chemical compound O[C@@H](CNCC=1C=C2CN(C(C2=CC=1)=O)CCN1CCC(CC1)OC(NC1=C(C=CC=C1)C1=CC=CC=C1)=O)C1=C2C=CC(NC2=C(C=C1)O)=O AUFQZFWXAANTNY-BHVANESWSA-N 0.000 description 2
- HPLLOJOBNBACNB-LHEWISCISA-N [1-[2-[6-[[[(2R)-2-hydroxy-2-(8-hydroxy-2-oxo-1H-quinolin-5-yl)ethyl]amino]methyl]-4,4-dimethyl-1-oxo-3H-isoquinolin-2-yl]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate Chemical compound O[C@@H](CNCC=1C=C2C(CN(C(C2=CC=1)=O)CCN1CCC(CC1)OC(NC1=C(C=CC=C1)C1=CC=CC=C1)=O)(C)C)C1=C2C=CC(NC2=C(C=C1)O)=O HPLLOJOBNBACNB-LHEWISCISA-N 0.000 description 2
- GGMWOCHEXJJKBH-QNGWXLTQSA-N [1-[2-[7-[[[(2R)-2-hydroxy-2-(8-hydroxy-2-oxo-1H-quinolin-5-yl)ethyl]amino]methyl]-1-oxo-3,4-dihydroisoquinolin-2-yl]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate Chemical compound O[C@@H](CNCC1=CC=C2CCN(C(C2=C1)=O)CCN1CCC(CC1)OC(NC1=C(C=CC=C1)C1=CC=CC=C1)=O)C1=C2C=CC(NC2=C(C=C1)O)=O GGMWOCHEXJJKBH-QNGWXLTQSA-N 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 210000005091 airway smooth muscle Anatomy 0.000 description 2
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 2
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 2
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229940124630 bronchodilator Drugs 0.000 description 2
- 239000000168 bronchodilator agent Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000013262 cAMP assay Methods 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 125000005215 cycloalkylheteroaryl group Chemical group 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- FMVKTTLEYWLPAU-LURJTMIESA-N diazonio-[(2r)-2-hydroxy-2-(4-hydroxy-2-oxo-3h-1,3-benzothiazol-7-yl)ethyl]azanide Chemical compound [N-]=[N+]=NC[C@H](O)C1=CC=C(O)C2=C1SC(=O)N2 FMVKTTLEYWLPAU-LURJTMIESA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229960001361 ipratropium bromide Drugs 0.000 description 2
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 229960002329 methacholine Drugs 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 125000005704 oxymethylene group Chemical group [H]C([H])([*:2])O[*:1] 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 2
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229960002052 salbutamol Drugs 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- PRBHEGAFLDMLAL-GQCTYLIASA-N (4e)-hexa-1,4-diene Chemical compound C\C=C\CC=C PRBHEGAFLDMLAL-GQCTYLIASA-N 0.000 description 1
- PMJHHCWVYXUKFD-SNAWJCMRSA-N (E)-1,3-pentadiene Chemical compound C\C=C\C=C PMJHHCWVYXUKFD-SNAWJCMRSA-N 0.000 description 1
- IGERFAHWSHDDHX-UHFFFAOYSA-N 1,3-dioxanyl Chemical group [CH]1OCCCO1 IGERFAHWSHDDHX-UHFFFAOYSA-N 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- ILWJAOPQHOZXAN-UHFFFAOYSA-N 1,3-dithianyl Chemical group [CH]1SCCCS1 ILWJAOPQHOZXAN-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- 125000006025 1-methyl-1-butenyl group Chemical group 0.000 description 1
- 125000006044 1-methyl-1-pentenyl group Chemical group 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- OHZAHWOAMVVGEL-UHFFFAOYSA-N 2,2'-bithiophene Chemical group C1=CSC(C=2SC=CC=2)=C1 OHZAHWOAMVVGEL-UHFFFAOYSA-N 0.000 description 1
- FHSOZUQQOSJYGE-UHFFFAOYSA-N 2-[1-oxo-2-[2-[4-[(2-phenylphenyl)carbamoyloxy]piperidin-1-yl]ethyl]-3H-isoindol-5-yl]ethanesulfonic acid Chemical compound C1CN(CCC1OC(=O)NC2=CC=CC=C2C3=CC=CC=C3)CCN4CC5=C(C4=O)C=CC(=C5)CCS(=O)(=O)O FHSOZUQQOSJYGE-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000006045 2-methyl-1-pentenyl group Chemical group 0.000 description 1
- 125000004398 2-methyl-2-butyl group Chemical group CC(C)(CC)* 0.000 description 1
- 125000006031 2-methyl-3-butenyl group Chemical group 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- 125000004917 3-methyl-2-butyl group Chemical group CC(C(C)*)C 0.000 description 1
- 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 1
- MDHKCIIEVIPVLU-JERHFGHZSA-M 4-[(1r)-2-[6-[2-[(2,6-dichlorophenyl)methoxy]ethoxy]hexylamino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol;diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol;bromide Chemical compound [Br-].C1=C(O)C(CO)=CC([C@@H](O)CNCCCCCCOCCOCC=2C(=CC=CC=2Cl)Cl)=C1.C=1C=CC=CC=1C(C12CC[N+](CCOCC=3C=CC=CC=3)(CC1)CC2)(O)C1=CC=CC=C1 MDHKCIIEVIPVLU-JERHFGHZSA-M 0.000 description 1
- 125000006042 4-hexenyl group Chemical group 0.000 description 1
- 125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 1
- GCUZFFAPBPDIFM-IKXQUJFKSA-M 5-[(1r)-2-[(5,6-diethyl-2,3-dihydro-1h-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1h-quinolin-2-one;(1,1-dimethylpyrrolidin-1-ium-3-yl) 2-cyclopentyl-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1.N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 GCUZFFAPBPDIFM-IKXQUJFKSA-M 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- QIGMCMVDPBLAND-INIZCTEOSA-N 7-[(1R)-2-azido-1-[tert-butyl(dimethyl)silyl]oxyethyl]-4-[tert-butyl(dimethyl)silyl]oxy-3H-1,3-benzothiazol-2-one Chemical compound N(=[N+]=[N-])C[C@H](O[Si](C)(C)C(C)(C)C)C1=CC=C(C=2NC(SC=21)=O)O[Si](C)(C)C(C)(C)C QIGMCMVDPBLAND-INIZCTEOSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- HOSFSGBFRDYFPR-UHFFFAOYSA-N C(C)(=O)O.NCCC1=CC=C(C=2NC(COC21)=O)O Chemical compound C(C)(=O)O.NCCC1=CC=C(C=2NC(COC21)=O)O HOSFSGBFRDYFPR-UHFFFAOYSA-N 0.000 description 1
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
- 241000720974 Protium Species 0.000 description 1
- BPZSYCZIITTYBL-YJYMSZOUSA-N R-Formoterol Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-YJYMSZOUSA-N 0.000 description 1
- KAEGGIFPLJZUOZ-UHFFFAOYSA-N Renilla luciferin Chemical compound C1=CC(O)=CC=C1C(N1)=CN2C(=O)C(CC=3C=CC=CC=3)=NC2=C1CC1=CC=CC=C1 KAEGGIFPLJZUOZ-UHFFFAOYSA-N 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- PEJHHXHHNGORMP-UHFFFAOYSA-M Umeclidinium bromide Chemical compound [Br-].C=1C=CC=CC=1C(C12CC[N+](CCOCC=3C=CC=CC=3)(CC1)CC2)(O)C1=CC=CC=C1 PEJHHXHHNGORMP-UHFFFAOYSA-M 0.000 description 1
- NPXZKPMDXMXGDW-UHFFFAOYSA-N [1-(2-aminoethyl)piperidin-4-yl] n-(2-phenylphenyl)carbamate Chemical compound C1CN(CCN)CCC1OC(=O)NC1=CC=CC=C1C1=CC=CC=C1 NPXZKPMDXMXGDW-UHFFFAOYSA-N 0.000 description 1
- HEAOAFSLXVKJCT-UHFFFAOYSA-N [1-[2-(6-formyl-1-oxo-3,4-dihydroisoquinolin-2-yl)ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate Chemical compound C(=O)C=1C=C2CCN(C(C2=CC=1)=O)CCN1CCC(CC1)OC(NC1=C(C=CC=C1)C1=CC=CC=C1)=O HEAOAFSLXVKJCT-UHFFFAOYSA-N 0.000 description 1
- WFFBONYCQXXOSU-UHFFFAOYSA-N [1-[2-(6-formyl-3-oxo-1H-isoindol-2-yl)ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate Chemical compound C(=O)C=1C=C2CN(C(C2=CC=1)=O)CCN1CCC(CC1)OC(NC1=C(C=CC=C1)C1=CC=CC=C1)=O WFFBONYCQXXOSU-UHFFFAOYSA-N 0.000 description 1
- PIMQEBQSDKKOHO-UHFFFAOYSA-N [1-[2-(6-formyl-4,4-dimethyl-1-oxo-3H-isoquinolin-2-yl)ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate Chemical compound C(=O)C=1C=C2C(CN(C(C2=CC=1)=O)CCN1CCC(CC1)OC(NC1=C(C=CC=C1)C1=CC=CC=C1)=O)(C)C PIMQEBQSDKKOHO-UHFFFAOYSA-N 0.000 description 1
- MSABGHVEVOVFHC-UHFFFAOYSA-N [1-[2-(7-formyl-1-oxo-3,4-dihydroisoquinolin-2-yl)ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate Chemical compound C(=O)C1=CC=C2CCN(C(C2=C1)=O)CCN1CCC(CC1)OC(NC1=C(C=CC=C1)C1=CC=CC=C1)=O MSABGHVEVOVFHC-UHFFFAOYSA-N 0.000 description 1
- VTLOAGNYPUADRE-UHFFFAOYSA-N [1-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethyl]piperidin-4-yl] n-(2-phenylphenyl)carbamate Chemical compound C1CN(CCNC(=O)OC(C)(C)C)CCC1OC(=O)NC1=CC=CC=C1C1=CC=CC=C1 VTLOAGNYPUADRE-UHFFFAOYSA-N 0.000 description 1
- OHPFHMREEBUOLE-UHFFFAOYSA-N [1-[2-[6-(2-bromoethyl)-1-oxo-3,4-dihydroisoquinolin-2-yl]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate Chemical compound BrCCC=1C=C2CCN(C(C2=CC=1)=O)CCN1CCC(CC1)OC(NC1=C(C=CC=C1)C1=CC=CC=C1)=O OHPFHMREEBUOLE-UHFFFAOYSA-N 0.000 description 1
- CGRZNCXIKWFEPF-UHFFFAOYSA-N [1-[2-[6-(2-bromoethyl)-3-oxo-1H-isoindol-2-yl]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate Chemical compound BrCCC=1C=C2CN(C(C2=CC=1)=O)CCN1CCC(CC1)OC(NC1=C(C=CC=C1)C1=CC=CC=C1)=O CGRZNCXIKWFEPF-UHFFFAOYSA-N 0.000 description 1
- OXVNNWRUPIGSKO-UHFFFAOYSA-N [1-[2-[6-(2-hydroxyethyl)-1-oxo-3,4-dihydroisoquinolin-2-yl]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate Chemical compound OCCC=1C=C2CCN(C(C2=CC=1)=O)CCN1CCC(CC1)OC(NC1=C(C=CC=C1)C1=CC=CC=C1)=O OXVNNWRUPIGSKO-UHFFFAOYSA-N 0.000 description 1
- ZSECZDQXTTUNRP-UHFFFAOYSA-N [1-[2-[6-(2-hydroxyethyl)-3-oxo-1H-isoindol-2-yl]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate Chemical compound OCCC=1C=C2CN(C(C2=CC=1)=O)CCN1CCC(CC1)OC(NC1=C(C=CC=C1)C1=CC=CC=C1)=O ZSECZDQXTTUNRP-UHFFFAOYSA-N 0.000 description 1
- RBRIRUHEKYMJSM-UHFFFAOYSA-N [1-[2-[6-(cyanomethyl)-1-oxo-3,4-dihydroisoquinolin-2-yl]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate Chemical compound C(#N)CC=1C=C2CCN(C(C2=CC=1)=O)CCN1CCC(CC1)OC(NC1=C(C=CC=C1)C1=CC=CC=C1)=O RBRIRUHEKYMJSM-UHFFFAOYSA-N 0.000 description 1
- NGZBBODLSHULBG-UHFFFAOYSA-N [1-[2-[6-(cyanomethyl)-3-oxo-1H-isoindol-2-yl]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate Chemical compound C(#N)CC=1C=C2CN(C(C2=CC=1)=O)CCN1CCC(CC1)OC(NC1=C(C=CC=C1)C1=CC=CC=C1)=O NGZBBODLSHULBG-UHFFFAOYSA-N 0.000 description 1
- RHCGVQRXZARCEP-UHFFFAOYSA-N [1-[2-[6-(hydroxymethyl)-1-oxo-3,4-dihydroisoquinolin-2-yl]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate Chemical compound OCC=1C=C2CCN(C(C2=CC=1)=O)CCN1CCC(CC1)OC(NC1=C(C=CC=C1)C1=CC=CC=C1)=O RHCGVQRXZARCEP-UHFFFAOYSA-N 0.000 description 1
- RJOIEVZVSKYVCJ-UHFFFAOYSA-N [1-[2-[6-(hydroxymethyl)-3-oxo-1H-isoindol-2-yl]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate Chemical compound OCC=1C=C2CN(C(C2=CC=1)=O)CCN1CCC(CC1)OC(NC1=C(C=CC=C1)C1=CC=CC=C1)=O RJOIEVZVSKYVCJ-UHFFFAOYSA-N 0.000 description 1
- BHJZUAXPKAUCCE-UHFFFAOYSA-N [1-[2-[6-(hydroxymethyl)-4,4-dimethyl-1-oxo-3H-isoquinolin-2-yl]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate Chemical compound OCC=1C=C2C(CN(C(C2=CC=1)=O)CCN1CCC(CC1)OC(NC1=C(C=CC=C1)C1=CC=CC=C1)=O)(C)C BHJZUAXPKAUCCE-UHFFFAOYSA-N 0.000 description 1
- DPLOYAUTQRMHSC-FAIXQHPJSA-N [1-[2-[6-[2-[[(2R)-2-[tert-butyl(dimethyl)silyl]oxy-2-(4-hydroxy-2-oxo-3H-1,3-benzothiazol-7-yl)ethyl]amino]ethyl]-1-oxo-3,4-dihydroisoquinolin-2-yl]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate Chemical compound [Si](C)(C)(C(C)(C)C)O[C@@H](CNCCC=1C=C2CCN(C(C2=CC=1)=O)CCN1CCC(CC1)OC(NC1=C(C=CC=C1)C1=CC=CC=C1)=O)C1=CC=C(C=2NC(SC=21)=O)O DPLOYAUTQRMHSC-FAIXQHPJSA-N 0.000 description 1
- LXBBOTBITMUSEK-RWYGWLOXSA-N [1-[2-[6-[2-[[(2R)-2-[tert-butyl(dimethyl)silyl]oxy-2-(5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]ethyl]-1-oxo-3,4-dihydroisoquinolin-2-yl]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate Chemical compound [Si](C)(C)(C(C)(C)C)O[C@@H](CNCCC=1C=C2CCN(C(C2=CC=1)=O)CCN1CCC(CC1)OC(NC1=C(C=CC=C1)C1=CC=CC=C1)=O)C1=CC=C(C=2NC(COC=21)=O)O LXBBOTBITMUSEK-RWYGWLOXSA-N 0.000 description 1
- XMFSYJMGHDGAFN-QLKFWGTOSA-N [1-[2-[6-[2-[[(2R)-2-[tert-butyl(dimethyl)silyl]oxy-2-(8-hydroxy-2-oxo-1H-quinolin-5-yl)ethyl]amino]ethyl]-1-oxo-3,4-dihydroisoquinolin-2-yl]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate Chemical compound [Si](C)(C)(C(C)(C)C)O[C@@H](CNCCC=1C=C2CCN(C(C2=CC=1)=O)CCN1CCC(CC1)OC(NC1=C(C=CC=C1)C1=CC=CC=C1)=O)C1=C2C=CC(NC2=C(C=C1)O)=O XMFSYJMGHDGAFN-QLKFWGTOSA-N 0.000 description 1
- MIUDEZSUPQMKRI-WBCKFURZSA-N [1-[2-[6-[2-[[(2R)-2-[tert-butyl(dimethyl)silyl]oxy-2-(8-hydroxy-2-oxo-1H-quinolin-5-yl)ethyl]amino]ethyl]-3-oxo-1H-isoindol-2-yl]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate Chemical compound [Si](C)(C)(C(C)(C)C)O[C@@H](CNCCC=1C=C2CN(C(C2=CC=1)=O)CCN1CCC(CC1)OC(NC1=C(C=CC=C1)C1=CC=CC=C1)=O)C1=C2C=CC(NC2=C(C=C1)O)=O MIUDEZSUPQMKRI-WBCKFURZSA-N 0.000 description 1
- CBNMYXNPHZQBIU-WBCKFURZSA-N [1-[2-[6-[[(2R)-2-[tert-butyl(dimethyl)silyl]oxy-2-(8-hydroxy-2-oxo-1H-quinolin-5-yl)ethyl]amino]-4,4-dimethyl-1-oxo-3H-isoquinolin-2-yl]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate Chemical compound [Si](C)(C)(C(C)(C)C)O[C@@H](CNC=1C=C2C(CN(C(C2=CC=1)=O)CCN1CCC(CC1)OC(NC1=C(C=CC=C1)C1=CC=CC=C1)=O)(C)C)C1=C2C=CC(NC2=C(C=C1)O)=O CBNMYXNPHZQBIU-WBCKFURZSA-N 0.000 description 1
- DEPZBWMSFDSQKY-UHFFFAOYSA-N [1-[2-[6-[[2-(5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl)ethylamino]methyl]-1-oxo-3,4-dihydroisoquinolin-2-yl]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate Chemical compound OC1=CC=C(C2=C1NC(CO2)=O)CCNCC=1C=C2CCN(C(C2=CC=1)=O)CCN1CCC(CC1)OC(NC1=C(C=CC=C1)C1=CC=CC=C1)=O DEPZBWMSFDSQKY-UHFFFAOYSA-N 0.000 description 1
- HRHZWKDKJNLEHY-FAIXQHPJSA-N [1-[2-[6-[[[(2R)-2-[tert-butyl(dimethyl)silyl]oxy-2-(5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]methyl]-1-oxo-3,4-dihydroisoquinolin-2-yl]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate Chemical compound [Si](C)(C)(C(C)(C)C)O[C@@H](CNCC=1C=C2CCN(C(C2=CC=1)=O)CCN1CCC(CC1)OC(NC1=C(C=CC=C1)C1=CC=CC=C1)=O)C1=CC=C(C=2NC(COC=21)=O)O HRHZWKDKJNLEHY-FAIXQHPJSA-N 0.000 description 1
- PHZRTNHRSYAZGR-WBCKFURZSA-N [1-[2-[6-[[[(2R)-2-[tert-butyl(dimethyl)silyl]oxy-2-(8-hydroxy-2-oxo-1H-quinolin-5-yl)ethyl]amino]methyl]-1-oxo-3,4-dihydroisoquinolin-2-yl]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate Chemical compound [Si](C)(C)(C(C)(C)C)O[C@@H](CNCC=1C=C2CCN(C(C2=CC=1)=O)CCN1CCC(CC1)OC(NC1=C(C=CC=C1)C1=CC=CC=C1)=O)C1=C2C=CC(NC2=C(C=C1)O)=O PHZRTNHRSYAZGR-WBCKFURZSA-N 0.000 description 1
- VDSZICFLPCKFAZ-RWYGWLOXSA-N [1-[2-[6-[[[(2R)-2-[tert-butyl(dimethyl)silyl]oxy-2-(8-hydroxy-2-oxo-1H-quinolin-5-yl)ethyl]amino]methyl]-3-oxo-1H-isoindol-2-yl]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate Chemical compound [Si](C)(C)(C(C)(C)C)O[C@@H](CNCC=1C=C2CN(C(C2=CC=1)=O)CCN1CCC(CC1)OC(NC1=C(C=CC=C1)C1=CC=CC=C1)=O)C1=C2C=CC(NC2=C(C=C1)O)=O VDSZICFLPCKFAZ-RWYGWLOXSA-N 0.000 description 1
- JXJOQRICZDSFRA-DHUJRADRSA-N [1-[2-[6-[[[(2R)-2-hydroxy-2-(5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl)ethyl]amino]methyl]-1-oxo-3,4-dihydroisoquinolin-2-yl]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate Chemical compound O[C@@H](CNCC=1C=C2CCN(C(C2=CC=1)=O)CCN1CCC(CC1)OC(NC1=C(C=CC=C1)C1=CC=CC=C1)=O)C1=CC=C(C=2NC(COC=21)=O)O JXJOQRICZDSFRA-DHUJRADRSA-N 0.000 description 1
- RFMNRJOPMGTULW-UHFFFAOYSA-N [1-[2-[6-[[tert-butyl(dimethyl)silyl]oxymethyl]-1-oxo-3,4-dihydroisoquinolin-2-yl]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate Chemical compound [Si](C)(C)(C(C)(C)C)OCC=1C=C2CCN(C(C2=CC=1)=O)CCN1CCC(CC1)OC(NC1=C(C=CC=C1)C1=CC=CC=C1)=O RFMNRJOPMGTULW-UHFFFAOYSA-N 0.000 description 1
- ZGHASEFNACTGLJ-UHFFFAOYSA-N [1-[2-[6-[[tert-butyl(dimethyl)silyl]oxymethyl]-4,4-dimethyl-1-oxo-3H-isoquinolin-2-yl]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate Chemical compound [Si](C)(C)(C(C)(C)C)OCC=1C=C2C(CN(C(C2=CC=1)=O)CCN1CCC(CC1)OC(NC1=C(C=CC=C1)C1=CC=CC=C1)=O)(C)C ZGHASEFNACTGLJ-UHFFFAOYSA-N 0.000 description 1
- OCORPBVINOBHOO-UHFFFAOYSA-N [1-[2-[7-(hydroxymethyl)-1-oxo-3,4-dihydroisoquinolin-2-yl]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate Chemical compound OCC1=CC=C2CCN(C(C2=C1)=O)CCN1CCC(CC1)OC(NC1=C(C=CC=C1)C1=CC=CC=C1)=O OCORPBVINOBHOO-UHFFFAOYSA-N 0.000 description 1
- DNSXTXFABOVOHE-WBCKFURZSA-N [1-[2-[7-[[[(2R)-2-[tert-butyl(dimethyl)silyl]oxy-2-(8-hydroxy-2-oxo-1H-quinolin-5-yl)ethyl]amino]methyl]-1-oxo-3,4-dihydroisoquinolin-2-yl]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate Chemical compound [Si](C)(C)(C(C)(C)C)O[C@@H](CNCC1=CC=C2CCN(C(C2=C1)=O)CCN1CCC(CC1)OC(NC1=C(C=CC=C1)C1=CC=CC=C1)=O)C1=C2C=CC(NC2=C(C=C1)O)=O DNSXTXFABOVOHE-WBCKFURZSA-N 0.000 description 1
- GBDIJCYXPXZUJB-UHFFFAOYSA-N [1-[2-[7-[[tert-butyl(dimethyl)silyl]oxymethyl]-1-oxo-3,4-dihydroisoquinolin-2-yl]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate Chemical compound [Si](C)(C)(C(C)(C)C)OCC1=CC=C2CCN(C(C2=C1)=O)CCN1CCC(CC1)OC(NC1=C(C=CC=C1)C1=CC=CC=C1)=O GBDIJCYXPXZUJB-UHFFFAOYSA-N 0.000 description 1
- HWIQYZQGAWDRKM-UHFFFAOYSA-N [1-oxo-2-[2-[4-[(2-phenylphenyl)carbamoyloxy]piperidin-1-yl]ethyl]-3,4-dihydroisoquinolin-6-yl]methyl methanesulfonate Chemical compound CS(=O)(=O)OCC=1C=C2CCN(C(C2=CC=1)=O)CCN1CCC(CC1)OC(NC1=C(C=CC=C1)C1=CC=CC=C1)=O HWIQYZQGAWDRKM-UHFFFAOYSA-N 0.000 description 1
- JUGOREOARAHOCO-UHFFFAOYSA-M acetylcholine chloride Chemical compound [Cl-].CC(=O)OCC[N+](C)(C)C JUGOREOARAHOCO-UHFFFAOYSA-M 0.000 description 1
- 229960004266 acetylcholine chloride Drugs 0.000 description 1
- 229960005012 aclidinium bromide Drugs 0.000 description 1
- XLAKJQPTOJHYDR-QTQXQZBYSA-M aclidinium bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C=3SC=CC=3)C=3SC=CC=3)[N+]21CCCOC1=CC=CC=C1 XLAKJQPTOJHYDR-QTQXQZBYSA-M 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 108010041089 apoaequorin Proteins 0.000 description 1
- 229960001692 arformoterol Drugs 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 102000015005 beta-adrenergic receptor activity proteins Human genes 0.000 description 1
- 108040006818 beta-adrenergic receptor activity proteins Proteins 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000004044 bronchoconstricting agent Substances 0.000 description 1
- 230000003435 bronchoconstrictive effect Effects 0.000 description 1
- 230000003182 bronchodilatating effect Effects 0.000 description 1
- 230000007883 bronchodilation Effects 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000002993 cycloalkylene group Chemical group 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- UTIKNGRWJJKNBJ-UHFFFAOYSA-N dimethyl 2-(bromomethyl)benzene-1,4-dicarboxylate Chemical compound COC(=O)C1=CC=C(C(=O)OC)C(CBr)=C1 UTIKNGRWJJKNBJ-UHFFFAOYSA-N 0.000 description 1
- DXIRJLBDSXBZCS-UHFFFAOYSA-N dimethyl 2-methylbenzene-1,4-dicarboxylate Chemical compound COC(=O)C1=CC=C(C(=O)OC)C(C)=C1 DXIRJLBDSXBZCS-UHFFFAOYSA-N 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 230000003086 effect on acetylcholine Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- GWAHMDXGIMEXRA-UHFFFAOYSA-N ethyl 2-[1-oxo-2-[2-[4-[(2-phenylphenyl)carbamoyloxy]piperidin-1-yl]ethyl]-3,4-dihydroisoquinolin-6-yl]acetate Chemical compound O=C1N(CCC2=CC(=CC=C12)CC(=O)OCC)CCN1CCC(CC1)OC(NC1=C(C=CC=C1)C1=CC=CC=C1)=O GWAHMDXGIMEXRA-UHFFFAOYSA-N 0.000 description 1
- IBPGBVFCNPKDGO-UHFFFAOYSA-N ethyl 2-[1-oxo-2-[2-[4-[(2-phenylphenyl)carbamoyloxy]piperidin-1-yl]ethyl]-3H-isoindol-5-yl]acetate Chemical compound O=C1N(CC2=CC(=CC=C12)CC(=O)OCC)CCN1CCC(CC1)OC(NC1=C(C=CC=C1)C1=CC=CC=C1)=O IBPGBVFCNPKDGO-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Substances O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 229960002848 formoterol Drugs 0.000 description 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940092682 glycopyrrolate / indacaterol Drugs 0.000 description 1
- 229960002462 glycopyrronium bromide Drugs 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- 125000005844 heterocyclyloxy group Chemical group 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229960004078 indacaterol Drugs 0.000 description 1
- QZZUEBNBZAPZLX-QFIPXVFZSA-N indacaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 QZZUEBNBZAPZLX-QFIPXVFZSA-N 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 230000003434 inspiratory effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000008263 liquid aerosol Substances 0.000 description 1
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 125000003585 oxepinyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229960001609 oxitropium bromide Drugs 0.000 description 1
- LCELQERNWLBPSY-KHSTUMNDSA-M oxitropium bromide Chemical compound [Br-].C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CC)=CC=CC=C1 LCELQERNWLBPSY-KHSTUMNDSA-M 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- PMJHHCWVYXUKFD-UHFFFAOYSA-N piperylene Natural products CC=CC=C PMJHHCWVYXUKFD-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
- 229940074439 potassium sodium tartrate Drugs 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000006085 pyrrolopyridyl group Chemical group 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
- XHFLOLLMZOTPSM-UHFFFAOYSA-M sodium;hydrogen carbonate;hydrate Chemical class [OH-].[Na+].OC(O)=O XHFLOLLMZOTPSM-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- TZRQZPMQUXEZMC-UHFFFAOYSA-N tert-butyl n-(2-bromoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCBr TZRQZPMQUXEZMC-UHFFFAOYSA-N 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical compound C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000005308 thiazepinyl group Chemical group S1N=C(C=CC=C1)* 0.000 description 1
- 125000003777 thiepinyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 238000002877 time resolved fluorescence resonance energy transfer Methods 0.000 description 1
- 229960000257 tiotropium bromide Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229960004541 umeclidinium bromide Drugs 0.000 description 1
- PEJHHXHHNGORMP-AVADPIKZSA-M umeclidinium bromide Chemical compound [Br-].C=1C=CC=CC=1C([C@@]12CC[N@@+](CCOCC=3C=CC=CC=3)(CC1)CC2)(O)C1=CC=CC=C1 PEJHHXHHNGORMP-AVADPIKZSA-M 0.000 description 1
- 230000001515 vagal effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229960004026 vilanterol Drugs 0.000 description 1
- DAFYYTQWSAWIGS-DEOSSOPVSA-N vilanterol Chemical compound C1=C(O)C(CO)=CC([C@@H](O)CNCCCCCCOCCOCC=2C(=CC=CC=2Cl)Cl)=C1 DAFYYTQWSAWIGS-DEOSSOPVSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2015109916200 | 2015-12-25 | ||
| CN201510991620 | 2015-12-25 | ||
| CN2016109431806 | 2016-10-26 | ||
| CN201610943180 | 2016-10-26 | ||
| PCT/CN2016/110670 WO2017107877A1 (fr) | 2015-12-25 | 2016-12-19 | Dérivé de biphényle, et son procédé de préparation et son utilisation à des fins médicales |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107849014A CN107849014A (zh) | 2018-03-27 |
| CN107849014B true CN107849014B (zh) | 2021-07-09 |
Family
ID=59089133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201680042175.6A Expired - Fee Related CN107849014B (zh) | 2015-12-25 | 2016-12-19 | 一种联苯衍生物及其制备方法和在医药上的用途 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN107849014B (fr) |
| WO (1) | WO2017107877A1 (fr) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002517464A (ja) * | 1998-06-08 | 2002-06-18 | アドバンスド メディスン インコーポレーテッド | ムスカリン性レセプターアンタゴニスト |
| US7479562B2 (en) * | 2005-03-10 | 2009-01-20 | Theravance, Inc. | Biphenyl compounds useful as muscarinic receptor antagonists |
| US7612085B2 (en) * | 2006-07-11 | 2009-11-03 | Washington University | Sigma 2 receptor ligands and therapeutic uses therefor |
-
2016
- 2016-12-19 CN CN201680042175.6A patent/CN107849014B/zh not_active Expired - Fee Related
- 2016-12-19 WO PCT/CN2016/110670 patent/WO2017107877A1/fr active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| CN107849014A (zh) | 2018-03-27 |
| WO2017107877A1 (fr) | 2017-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012312305B2 (en) | Acyclic cyanoethylpyrazoles as janus kinase inhibitors | |
| KR101088247B1 (ko) | 크로메인 치환된 벤즈이미다졸 및 이들의 산 펌프억제제로서의 용도 | |
| JP2022511213A (ja) | 細胞壊死阻害剤、その調製方法およびその使用 | |
| KR20170115069A (ko) | 무스카린성 수용체 길항제 및 베타2 아드레날린성 수용체 효능제 활성을 가지는 화합물 | |
| CN107074833B (zh) | 具有β2受体激动及M3受体拮抗活性的苯并环衍生物及其在医药上的用途 | |
| CN107849047B (zh) | 一种联苯衍生物及其制备方法和在医药上的用途 | |
| CN106565674B (zh) | 一种八氢环戊烷并[c]吡咯衍生物及其制备方法和在医药上的用途 | |
| CA3010660A1 (fr) | Derive d'amide heterocyclique azote, procede de preparation associe et application phramaceutique | |
| AU2012327076B2 (en) | Bicyclic heterocyclic compound | |
| CN107108502A (zh) | 具有β2受体激动及M受体拮抗活性的联苯衍生物及其在医药上的用途 | |
| CN110248658B (zh) | 吗啡喃衍生物的在阿片δ受体激动剂相关疾病的治疗中的应用 | |
| JP6200495B2 (ja) | α−置換グリシンアミド誘導体 | |
| CN107074816B (zh) | 一种杂环衍生物及其制备方法和在医药上的用途 | |
| CN107849014B (zh) | 一种联苯衍生物及其制备方法和在医药上的用途 | |
| CN107108562B (zh) | 具有β2受体激动及M受体拮抗活性的含氮杂螺环衍生物及其在医药上的用途 | |
| CN106336406B (zh) | 具有β2受体激动及M受体拮抗活性的八氢并环戊二烯衍生物及其在医药上的用途 | |
| CN111423434A (zh) | 一种碳酰胺衍生物及其制备方法 | |
| CN110590776A (zh) | 一种联苯衍生物及其制备方法和在医药上的用途 | |
| CN109195975B (zh) | 一种二氮杂螺[5.5]十一碳烷衍生物及其用途 | |
| CN107849035B (zh) | 一种苯基杂环衍生物及其在医药上的用途 | |
| KR20080108129A (ko) | 크로메인 유도체 | |
| JP2016094407A (ja) | 新規なｔｒｐｍ８阻害薬 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210709 |